Shoulder Innovations stock initiated with Buy rating by BTIG

Investing.com - BTIG initiated coverage on Shoulder Innovations (NYSE:SI) with a Buy rating and a $23.00 price target on Monday. The company, currently valued at $281 million, has seen its stock decline by about 11% over the past week, trading at $12.71.

The medical technology company focuses on the shoulder arthroplasty market, which BTIG describes as a high-growth segment within the broader musculoskeletal market. The firm highlighted SI’s flagship product, the InSet Glenoid, which is designed to address common complications in shoulder arthroplasty such as glenoid loosening. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 7.1, indicating robust operational flexibility.

BTIG noted that while traditional shoulder implants can have up to approximately 40% revision rates, SI’s InSet Glenoid has recorded zero revisions over a 10+ year span in clinical literature. The firm also pointed to the robust shoulder implant market, valued at approximately $1.7 billion in the US and growing at high single digits. With annual revenue of $34.6 million and a healthy gross profit margin of 77%, the company shows promising fundamentals despite not yet achieving profitability. Discover more detailed financial metrics and insights with InvestingPro, which offers 6 additional key tips for this stock.

The research firm emphasized that SI’s management team previously worked at Tornier NV, which was acquired by Wright Medical and subsequently by Stryker (NYSE:SYK). This experience, according to BTIG, has enabled them to build a "purposeful, high-growth company."

BTIG projects Shoulder Innovations to grow at approximately 33% top-line compound annual growth rate through fiscal year 2027, which the firm notes is above industry peers.

In other recent news, several financial firms have initiated coverage on Shoulder Innovations, reflecting a positive outlook on the company. Piper Sandler started with an Overweight rating, setting a price target of $18.00, emphasizing the company’s role in the $2 billion shoulder replacement market. Jefferies also initiated coverage with a Buy rating and a $19.00 price target, highlighting anticipated market share gains and estimating the target as approximately five times the company’s projected 2026 sales. Goldman Sachs joined the positive sentiment with a Buy rating and a $20.00 price target, noting the company’s revenue growth and potential upside in its valuation. These recent developments suggest a strong interest in Shoulder Innovations from major financial analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.